Trial
NCT05992922
A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Iacta Pharmaceuticals
Collaborators
—
Condition
Dry Eye Syndromes
Intervention
IC265 Ophthalmic Solution 1%
Why stopped
Unexpected adverse events were observed in a subset of patients on drug. In an over abundance of caution the study was terminated. All adverse events resolved with no sequelae.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-25